Abstract
Recent discoveries have significantly enhanced our understanding of the biology of pediatric central nervous system tumors. Molecularly defined targeted therapies are now being used to treat subgroups of these tumors, mostly in the setting of clinical trials. These therapies include targeted inhibition of smoothened to treat sonic hedgehog medulloblastoma; of mammalian target of rapamycin to treat subependymal giant cell astrocytoma; and of the mitogen-activated protein kinase pathway to treat BRAF V600E-mutated low-grade and high-grade gliomas, KIAA1549:BRAF fusion-positive pilocytic astrocytoma, and plexiform neurofibroma. For many patients, the use of these targeted therapies has resulted in significant regression and/or improved control of their tumors, including tumors that are recurrent or refractory to conventional therapy.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- CNS:
-
Central nervous system
- HGG:
-
High-grade glioma
- LGG:
-
Low-grade glioma
- MAPK:
-
Mitogen-activated protein kinase
- MEK:
-
Mitogen-activated extracellular signal-regulated kinase
- mTOR:
-
Mammalian target of rapamycin
- NF1:
-
Neurofibromatosis type 1
- PN:
-
Plexiform neurofibroma
- PTCH1:
-
Patched 1
- SEGA:
-
Subependymal giant cell astrocytoma
- SHH:
-
Sonic hedgehog
- SMO:
-
Smoothened
- SUFU:
-
Suppressor of fused
- TSC:
-
Tuberous sclerosis complex
- WHO:
-
World Health Organization
References
Ward E, et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83–103.
Curtin SC, Minino AM, Anderson RN. Declines in cancer death rates among children and adolescents in the United States, 1999–2014. NCHS Data Brief. 2016;257:1–8.
Louis DN, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.
Cavalli FMG, et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell. 2017;31(6):737–54. e6
Robinson GW, et al. Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032. J Clin Oncol. 2015;33(24):2646–54.
Rudin CM, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361(12):1173–8.
Rodon J, et al. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res. 2014;20(7):1900–9.
Berard CL. Study of vismodegib in combination with temozolomide versus temozolomide alone in patients with medulloblastomas with an activation of the sonic hedgehog pathway. In: ClinicalTrials.gov [Internet]. Bethesda: National Library of Medicine (US). 2000 [cited 2017 Jan 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01601184: NCT01601184.
St. Jude Children’s Research Hospital. A clinical and molecular risk-directed therapy for newly diagnosed medulloblastoma. In: ClinicalTrials.gov [Internet]. Bethesda: National Library of Medicine (US). 2000 [cited 2017 Jan 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01878617:NCT01878617.
Erivedge [package insert]. San Francisco: Genentech; 2012.
Lucas JT Jr, Wright KD. Vismodegib and physeal closure in a pediatric patient. Pediatr Blood Cancer. 2016;63(11):2058.
Krueger DA, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801–11.
Franz DN, et al. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. Ann Neurol. 2015;78(6):929–38.
Gajjar A, et al. Pediatric brain tumors: innovative genomic information is transforming the diagnostic and clinical landscape. J Clin Oncol. 2015;33(27):2986–98.
Gajjar A, et al. Molecular insights into pediatric brain tumors have the potential to transform therapy. Clin Cancer Res. 2014;20(22):5630–40.
Schindler G, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121(3):397–405.
Miller C, et al. Report of effective trametinib therapy in 2 children with progressive hypothalamic optic pathway pilocytic astrocytoma: documentation of volumetric response. J Neurosurg Pediatr. 2017;19(3):319–24.
Olow A, et al. BRAF status in personalizing treatment approaches for pediatric gliomas. Clin Cancer Res. 2016;22(21):5312–21.
Aguilera D, et al. Successful retreatment of a child with a refractory brainstem ganglioglioma with vemurafenib. Pediatr Blood Cancer. 2016;63(3):541–3.
Lassaletta A, et al. Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma. Pediatr Blood Cancer. 2016;63(11):2038–41.
Shih KC, et al. Successful treatment with dabrafenib (GSK2118436) in a patient with ganglioglioma. J Clin Oncol. 2014;32(29):e98–e100.
Su F, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207–15.
Bautista F, et al. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer. 2014;61(6):1101–3.
Lee EQ, et al. Successful treatment of a progressive BRAF V600E-mutated anaplastic pleomorphic xanthoastrocytoma with vemurafenib monotherapy. J Clin Oncol. 2016;34(10):e87–9.
Robinson GW, Orr BA, Gajjar A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer. 2014;14:258.
Dombi E, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med. 2016;375(26):2550–60.
Farid M, et al. Malignant peripheral nerve sheath tumors. Oncologist. 2014;19(2):193–201.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Whipple, N.S., Gajjar, A. (2019). Targeted Therapies for Pediatric Central Nervous System Tumors. In: Badve, S., Kumar, G. (eds) Predictive Biomarkers in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-95228-4_33
Download citation
DOI: https://doi.org/10.1007/978-3-319-95228-4_33
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95227-7
Online ISBN: 978-3-319-95228-4
eBook Packages: MedicineMedicine (R0)